Form 4 for EW Edwards Lifesciences
Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-07 · accession 0001225208-23-005622 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-09 | 2023-05-07+ | EW | Zovighian Bernard J | Pres | F - Tax | $88.74 | -3,756 | 22.0K | -15% | -$333.3K |
| D | 2023-05-09 | 2023-05-07 | EW | Zovighian Bernard J | Pres | M - OptEx | $0.00 | +5,003 | 25.8K | +24% | $0 |
| D | 2023-05-09 | 2023-05-07 | EW | Zovighian Bernard J | Pres | M - OptEx | $0.00 | -5,003 | 1,372 | -78% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-07 | F | D | 2,323 | $88.74 | 23,460.87 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-07 | M | A | 5,003 | $0.00 | 25,783.87 | D | — | — | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |
| 3 | Common | Common Stock | 2023-05-08 | F | D | 1,433 | $88.74 | 22,027.87 | D | — | — | |
| 4 | Derivative | Performance Rights | 2023-05-07 | M | D | 5,003 | $0.00 | 1,372 | D | $0.00 · 2023-05-07 to — | 5,003 Common Stock | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |